# Purple Biotech LTD.: Form 20-F for the period ended Dec 31, 2022

- Company: [Purple Biotech LTD.](/companies/ppbt.md) (CIK 1614744)
- Form: 20-F
- Filed: 2023-03-03
- Accepted by EDGAR: Mar 3, 2023, 07:56 ET
- Period: 2022-12-31
- Accession: 0001213900-23-017024
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1614744/000121390023017024/f20f2022_purplebiotech.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1614744/000121390023017024/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Net income | 12 months, 2022-01-01 to 2022-12-31 | $21.7m | ifrs-full:ProfitLossAttributableToOwnersOfParent |
| Capital expenditure | 12 months, 2022-01-01 to 2022-12-31 | $26.0k | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | at 2022-12-31 | $15.0m | ifrs-full:CashAndCashEquivalents |
| Current assets | at 2022-12-31 | $33.3m | ifrs-full:CurrentAssets |
| Total assets | at 2022-12-31 | $54.6m | ifrs-full:Assets |
| Current liabilities | at 2022-12-31 | $7.1m | ifrs-full:CurrentLiabilities |
| Shareholders' equity | at 2022-12-31 | $46.9m | ifrs-full:EquityAttributableToOwnersOfParent |
| Shares outstanding | at 2022-12-31 | 184,815,092 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1614744/000121390023017024/f20f2022_purplebiotech.htm

Filed Mar 3, 2023.
Source: SEC EDGAR, the filing index for accession 0001213900-23-017024. Last ingested by Listed: Nov 6, 2026, 18:16 ET. No prices; not investment advice.